瑞舒伐他汀对兔动脉粥样硬化斑块及炎症因子水平的影响

Rosuvastatin on rabbit atherosclerotic plaques and levels of inflammatory cytokines

目的探讨瑞舒伐他汀对兔动脉粥样硬化模型的斑块以及炎症因子的影响作用。方法将36只雄性新西兰家兔随机分为空白组、模型组以及瑞舒伐他汀组,每组12只,空白组家兔正常饲养,模型组与瑞舒伐他汀组家兔进行动脉粥样硬化(AS)造模,并对瑞舒伐他汀组家兔给予瑞舒伐他汀1.5 mg/(kg·d)。在治疗前、治疗4周、治疗8周以及治疗12周后对家兔的血脂水平以及炎症因子水平进行检测;在治疗结束后运用血管内超声显像仪对家兔的管腔面积狭窄的百分率LAS%进行比较。结果模型组治疗4周、治疗8周以及治疗12周血脂指标显著高于同时期空白组(P<0.05或P<0.01);瑞舒伐他汀组各指标水平比较仍为增长趋势,在治疗4周、治疗8周以及治疗12周后与空白组差异有统计学意义(P<0.05或P<0.01),但是与模型组相比,治疗后三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平显著低于模型组同时期水平(P<0.05或P<0.01)。对于模型组以及瑞舒伐他汀组动物,随着造模的进程,炎症因子单核细胞趋化因子(MCP-1)、肿瘤坏死因子-α(TNF-α)以及白介素-1(IL-1)水平在治疗4周、治疗8周以及治疗12周后均显著高于空白组(P<0.05或P<0.01)。瑞舒伐他汀组与模型组相比较,各炎症因子水平在治疗4周、治疗8周、治疗12周显著低于模型组(P<0.05或P<0.01)。瑞舒伐他汀组动物管腔面积狭窄百分率(LAS)为(28.79±4.71)%,模型组(LAP)为(36.67±5.48)%,两组比较差异有统计学意义(P<0.05)。结论瑞舒伐他汀能够较好地控制动脉粥样硬化模型兔的血脂水平以及炎症因子水平,减少动脉粥样硬化模型兔斑块的形成。

Objective To investigate the influence of Rosuvastatin on atherosclerosis plaques and inflammatory factors in rabbit model. Methods 36 male New Zealand rabbits were randomly divided into blank group,model group and Rosuvastatin group,with 12 rats in each group. The blank group was fed normally,the model group and Rosuvastatin group of rabbits were modeled by AS modeling,and the Rosuvastatin group of rabbits was fed with Rosuvastatin 1.5 mg/（kg·d）. Lipid levels and inflammatory factor levels were detected before treatment,4 weeks,8 weeks and 12 weeks after treatment. The lumen area stenosis percentage（LAS） was compared by intravascular ultrasound imaging device at the end of treatment. Results The model group for 4 weeks,8 weeks and 12 week treatment were significantly higher than that of the same period of lipids in blank group（P 0.05 or P 0.01）. Each index level of Rosuvastatin group was still increasing trend. Compared to the control group,there were significant differences after 4 weeks,8 weeks and 12 weeks of treatment（P 0.05 or P 0.01）. However,compared with the model group,the levels of riglyceride（TG）,total cholesterol（TC）,low density lipoprotein cholesterol（LDL-C） were significantly lower than those of the same period in the model group level（P 0.05 or P 0.01）. For the animals of the model group and the Rosuvastatin group,with the modeling process,monocyte chemoattractant factor（MCP-1）,tumor necrosis factor alpha（TNFα） and interleukin-1（IL-1） level were significantly higher than those in the blank group after 4 weeks,8 weeks and 12 weeks of treatment（P 0.05 or P 0.01）. Compared with the model group,the levels of inflammatory factors in rosuvastatin were significantly lower than those of the model group after 4 weeks,8 weeks and 12 weeks of treatment（P 0.05 or P 0.01）. The animals lumen area stenosis percentage（LAS） of rosuvastatin group was（28.79±4.71）%,the LAS in the model group was（36.67±5.48）%,two groups were significantly different（P 0.05）. Conclusion Rosuvastatin is better able to control the levels of lipid and inflammatory factors and reduce the plaque formation in the atherosclerosis model of rabbit.